Figure 1
Figure 1. High-level CXCR5 surface expression on CLL cells and normal CD5+ B cells. The top panel displays overlay histograms that depict the relative red fluorescence intensity after staining of CLL B cells, CXCR5-positive T cells (TFH cells), or neoplastic B cells from a patient with multiple myeloma with PE-labeled anti-CXCR5 mAbs (dark-gray histograms) or PE-conjugated isotype controls (light-gray histograms). CLL cells were identified by gating on the CD19-expressing cells, TFH cells by gating on the CD5+ and CXCR5-positive and CD19− lymphocytes, whereas multiple myeloma cells were gated by costaining with anti-CD38 and anti-CD138 mAbs. The CXCR5 mean fluorescence intensity ratio (MFIR) values are displayed next to each CXCR5 histogram. Compared with other B-cell neoplasias, TFH cells, or CD5− B cells, CLL B cells and normal CD5+ B cells consistently expressed higher levels of surface CXCR5, and multiple myeloma cells did not express surface CXCR5. The right-hand side box in the top panel displays a bar diagram that depicts the mean (± SEM) CXCR5 MFIRs for TFH cells (n = 3), normal CD5− B cells (n = 11), normal CD5+ B cells (n = 3), CLL B cells (n = 49), prolymphocytic leukemia cells (PLL, n = 3), follicular lymphoma cells (FCL, n = 2), mantle cell lymphoma cells (MCL, n = 2), immunocytoma (IC, n = 1), and multiple myeloma (MM, n = 3). The bottom panel displays contour plots that depict the staining and gating of buffy coat cells to determine CXCR5 expression on normal CD5+ B cells. A small proportion of circulating B cells coexpresses CD19 and CD5; this specimen had 10% CD19+ B cells, 0.8% CD19+/CD5+ B cells, and 65% CD5+ T cells, as indicated in the bottom left contour plot. Because of the low frequency of CD5+ B cells, we acquired 500 000 or more CD19+ B cells, which in this case contained 7.6% CD5+ B cells (middle contour plot). This allows us to determine CXCR5 expression levels on a sufficient number of CD19+/CD5+ B cells in gate R1. The right-hand histogram overlay displays the CXCR5 expression on CD5+ B cells in R1 (gray histogram), compared with the respective isotype control (white histogram), and the CXCR5 MFIR is displayed next to the CXCR5 histogram.

High-level CXCR5 surface expression on CLL cells and normal CD5+ B cells. The top panel displays overlay histograms that depict the relative red fluorescence intensity after staining of CLL B cells, CXCR5-positive T cells (TFH cells), or neoplastic B cells from a patient with multiple myeloma with PE-labeled anti-CXCR5 mAbs (dark-gray histograms) or PE-conjugated isotype controls (light-gray histograms). CLL cells were identified by gating on the CD19-expressing cells, TFH cells by gating on the CD5+ and CXCR5-positive and CD19− lymphocytes, whereas multiple myeloma cells were gated by costaining with anti-CD38 and anti-CD138 mAbs. The CXCR5 mean fluorescence intensity ratio (MFIR) values are displayed next to each CXCR5 histogram. Compared with other B-cell neoplasias, TFH cells, or CD5− B cells, CLL B cells and normal CD5+ B cells consistently expressed higher levels of surface CXCR5, and multiple myeloma cells did not express surface CXCR5. The right-hand side box in the top panel displays a bar diagram that depicts the mean (± SEM) CXCR5 MFIRs for TFH cells (n = 3), normal CD5− B cells (n = 11), normal CD5+ B cells (n = 3), CLL B cells (n = 49), prolymphocytic leukemia cells (PLL, n = 3), follicular lymphoma cells (FCL, n = 2), mantle cell lymphoma cells (MCL, n = 2), immunocytoma (IC, n = 1), and multiple myeloma (MM, n = 3). The bottom panel displays contour plots that depict the staining and gating of buffy coat cells to determine CXCR5 expression on normal CD5+ B cells. A small proportion of circulating B cells coexpresses CD19 and CD5; this specimen had 10% CD19+ B cells, 0.8% CD19+/CD5+ B cells, and 65% CD5+ T cells, as indicated in the bottom left contour plot. Because of the low frequency of CD5+ B cells, we acquired 500 000 or more CD19+ B cells, which in this case contained 7.6% CD5+ B cells (middle contour plot). This allows us to determine CXCR5 expression levels on a sufficient number of CD19+/CD5+ B cells in gate R1. The right-hand histogram overlay displays the CXCR5 expression on CD5+ B cells in R1 (gray histogram), compared with the respective isotype control (white histogram), and the CXCR5 MFIR is displayed next to the CXCR5 histogram.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal